Ilsung Pharm
Ilsung Is Co., Ltd. operates as a pharmaceutical company in South Korea. Its products include antibiotics, analgesics, muscle relaxants, antipyretic-analgesics, antihistamine, neuropsychiatric, neuromuscular blocker/ central muscle relaxants, anti-coagulants, probiotics, vaccine, medical equipment, circulatory system drugs, contrast agents, muscle relaxants, diabetes treatments, osteopathic, dige… Read more
Ilsung Pharm (003120) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.001x
Based on the latest financial reports, Ilsung Pharm (003120) has a cash flow conversion efficiency ratio of -0.001x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-371.10 Million) by net assets (₩376.56 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ilsung Pharm - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Ilsung Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Ilsung Pharm Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ilsung Pharm ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
WAREHOUSES EST.BELGIUM
F:WPK
|
N/A |
|
Yuken India Limited
NSE:YUKEN
|
0.020x |
|
Boilermech Holdings Bhd
KLSE:0168
|
0.044x |
|
Rubber Leaf Inc
OTCGREY:RLEA
|
-0.097x |
|
Consus Enerji Isletmeciligi ve Hizmetleri AS
IS:CONSE
|
0.196x |
|
Tsang Yow Industrial Co Ltd
TW:1568
|
0.030x |
|
Rego Payment Architectures Inc
OTCQB:RPMT
|
0.034x |
|
Tan Cang Logistics and Stevedoring JSC
VN:TCL
|
N/A |
Annual Cash Flow Conversion Efficiency for Ilsung Pharm (2013–2024)
The table below shows the annual cash flow conversion efficiency of Ilsung Pharm from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩385.13 Billion | ₩-4.26 Billion | -0.011x | +89.80% |
| 2023-12-31 | ₩382.75 Billion | ₩-41.47 Billion | -0.108x | -23.91% |
| 2022-12-31 | ₩445.57 Billion | ₩-38.97 Billion | -0.087x | -630.33% |
| 2021-12-31 | ₩345.91 Billion | ₩5.70 Billion | 0.016x | +267.94% |
| 2020-12-31 | ₩347.48 Billion | ₩1.56 Billion | 0.004x | -64.72% |
| 2019-12-31 | ₩345.49 Billion | ₩4.39 Billion | 0.013x | -72.70% |
| 2018-12-31 | ₩324.34 Billion | ₩15.09 Billion | 0.047x | +47.86% |
| 2017-12-31 | ₩322.83 Billion | ₩10.16 Billion | 0.031x | +132.48% |
| 2016-12-31 | ₩320.10 Billion | ₩-31.01 Billion | -0.097x | -610.55% |
| 2015-12-31 | ₩318.34 Billion | ₩6.04 Billion | 0.019x | +48.84% |
| 2014-12-31 | ₩328.68 Billion | ₩4.19 Billion | 0.013x | -18.74% |
| 2013-12-31 | ₩322.74 Billion | ₩5.06 Billion | 0.016x | -- |